This House resolution formally recognizes President Donald J. Trump for various policies and actions that the West Virginia House of Delegates claims have benefited the state. The document highlights specific initiatives including regulatory reforms in the energy sector, tax relief measures, funding for rural healthcare, and programs aimed at reducing prescription drug costs and establishing investment accounts for newborns. It also cites border security improvements and drug control efforts as contributing factors to public safety and economic well-being. The resolution expresses appreciation for these actions and requests that the formal recognition be sent to the President.
This bill amends West Virginia's drug scheduling laws to allow the legal prescription, distribution, and marketing of crystalline polymorph psilocybin if it receives FDA approval and DEA rescheduling. The legislation specifically targets this particular form of psilocybin, which is a type of psychedelic compound, and would permit its use under federal regulatory frameworks. The bill requires the state Board of Pharmacy to align West Virginia's controlled substance schedules with federal actions regarding this specific psilocybin variant. It does not change the scheduling status of other drugs or expand access to psilocybin beyond the specific FDA-approved crystalline polymorph form. The measure affects healthcare providers, pharmacies, and patients who might access this substance through approved medical channels.
This bill establishes rules for pharmacy benefit managers operating in West Virginia to protect pharmacies and patients from unfair pricing practices. It requires these managers to provide information about lower-cost drug alternatives without penalizing pharmacies for discussing them, and it prohibits charging pharmacies more than the amount patients pay out of pocket. The legislation also restricts how pharmacy benefit managers can handle 340B drug discounts, ensuring 340B pharmacies are not charged additional fees or subjected to extra administrative burdens compared to other pharmacies. Additionally, the bill mandates an annual study of dispensing fees and requires the implementation of a pharmacy cost containment tool to help control drug spending.
This bill allows doctors in West Virginia to legally prescribe, distribute, and market specific forms of psilocybin once the FDA approves it and the DEA reschedules it. It amends state pharmacy laws to remove barriers for FDA-approved crystalline polymorph psilocybin products, aligning state regulations with federal decisions. The law applies only to pharmaceutical compositions of psilocybin that meet federal approval standards, not to raw or unapproved forms of the substance. Healthcare providers and pharmacies would be able to handle these medications under existing prescription drug frameworks once federal requirements are met.
HB 5144 establishes a state program to import prescription drugs from Canada, requiring the West Virginia Department of Health and Human Resources to design and implement it under federal approval (21 U.S.C. § 384). The program mandates that imported drugs meet FDA safety standards, generate significant consumer cost savings, and comply with federal tracking rules, while prohibiting distribution outside West Virginia. It requires the department to partner with licensed U.S. wholesalers, Canadian suppliers, and state health providers, create a public price website, and report annually on participation, drugs imported, and cost savings starting in 2027. This directly affects West Virginia consumers, pharmacies, health insurers, and healthcare providers participating in the importation program.
HB 5556 creates a three-year pilot program allowing West Virginia's Medicaid program to set drug reimbursement rates based on the lowest prices paid for similar drugs in other industrialized countries (external reference pricing). It targets high-cost prescription drugs significantly impacting Medicaid spending, while excluding drugs without international price comparisons and ensuring continued access to medically necessary medications. The program requires annual reports to lawmakers on cost savings, drug availability, and manufacturer participation, and permits the state to negotiate rebates or adjust rates to prevent shortages. This pilot applies only to Medicaid drugs and does not affect private insurance or existing pharmaceutical contracts.
HB 5470 requires pharmacy benefits managers to include all cost-sharing amounts paid by patients or others when calculating their out-of-pocket costs for prescriptions. It applies annual cost-sharing limits to all health plans sold in West Virginia and prohibits insurers or pharmacy managers from changing coverage terms based on the availability of drug assistance programs. The bill directly affects insured patients and health plans by preventing hidden cost-shifting and ensuring transparency in how deductibles and copays are calculated. Violations carry civil penalties up to $10,000 per incident, and the provisions take effect for plans issued on or after January 1, 2027.
HB 5591 (West Virginia) allows pharmacists to dispense ivermectin to patients without a prescription, provided they follow standardized protocols established by the state pharmacy board. It protects pharmacists from criminal, civil, or professional disciplinary action when dispensing under these protocols. The bill directly affects pharmacists and patients seeking ivermectin for human use, removing the current prescription requirement. The pharmacy board may create specific rules for implementation through the legislative process.
HB 5553 allows West Virginia's Public Employees Insurance Agency (PEIA) and the Department of Human Services to voluntarily join federal prescription drug pricing programs, such as those using international reference pricing models. The bill permits these agencies to negotiate drug prices directly with manufacturers or use federal benchmarks for reimbursement, but only if it saves money for the state and maintains beneficiary access to necessary medications. It explicitly prohibits requiring the state to adopt federal drug lists or override existing state pharmacy benefit rules. Both agencies must report annually to the legislature on program participation, estimated savings, and any access issues.
SB 1028 requires health insurers and pharmacy benefit managers in West Virginia to include any cost-sharing payments made by patients or other sources (like drug assistance programs) when calculating a patient's out-of-pocket costs for prescription drugs. It sets an annual cap on out-of-pocket expenses for all health plans sold in the state and prohibits insurers from altering coverage terms based on whether a patient has access to drug discounts. This bill directly affects health insurers, pharmacy benefit managers, and third-party administrators operating in West Virginia. Violations could result in civil penalties of up to $10,000 per violation.
